Iron as a therapeutic target for Parkinson's disease

Caroline Moreau; James A Duce; Olivier Rascol; Jean-Christophe Devedjian; Daniela Berg; David Dexter; Z Ioav Cabantchik; Ashley I Bush; David Devos

Journal article

Iron as a therapeutic target for Parkinson's disease

Caroline Moreau, James A Duce, Olivier Rascol, Jean-Christophe Devedjian, Daniela Berg, David Dexter, Z Ioav Cabantchik, Ashley I Bush, David Devos

Movement Disorders | WILEY | Published : 2018

DOI: 10.1002/mds.27275

University of Melbourne Researchers

Ashley Bush Author Florey Department of Neuroscience and Mental Health

James Duce Author Florey Department of Neuroscience and Mental Health

Grants

Awarded by European Commission Horizon PHC

Funding Acknowledgements

This article refers to an academic study in progress with the French NS-Park network, which is funded by a grant from the European Commission Horizon 2020 PHC13 2014-2015 (633190): "Conservative iron chelation as a disease-modifying strategy in Parkinson's disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone (FAIR-PARK-II)"; protocol ID 2015_22; clinical trial: NCT02655315; http://fairpark2.eu. ApoPharma provided deferiprone and advice on the molecule.